Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 126638105 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Johnson & Johnson
13G/A
|
15.4% |
1/12/2026
Event 12/31/2025
|
||
| Johnson & Johnson | 15.4% | |||
| Johnson & Johnson Innovation - JJDC, Inc. | 15.4% | |||
|
New Enterprise Associates 10 L P
13D/A
|
7.8% |
2/20/2025
Event 2/18/2025
|
||
| New Enterprise Associates 10, Limited Partnership | 7.8% | |||
| New Enterprise Associates 8A, Limited Partnership | 0% | |||
| NEA Partners 10, Limited Partnership | 7.8% | |||
| New Enterprise Associates VIII, Limited Partnership | 0% | |||
| NEA Partners VIII, Limited Partnership | 0% | |||
| Anthony A. Florence, Jr. | 7.8% | |||
| Mohamad H. Makhzoumi | 7.8% | |||
| Scott D. Sandell | 7.8% | |||
|
Vensana Capital I GP, LLC
13G/A
|
7.2% |
2/6/2025
Event 12/31/2024
|
||
| Vensana Capital I GP, LLC | 7.1% | |||
| Vensana Capital I, L.P. | 7.1% | |||
| Kirk Nielsen | 7.2% | |||
| Peter Justin Klein | 7.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Cooperatieve Gilde Healthcare IV U.A.
13D/A
|
4.9% |
2/6/2025
Event 2/4/2025
|
||
| Cooperatieve Gilde Healthcare IV U.A. | 4.9% | |||
| Gilde Healthcare IV Management B.V. | 4.9% | |||
| Gilde Healthcare Holding B.V. | 4.9% | |||
| Manapouri B.V. | 4.9% | |||
| Martemanshurk B.V. | 4.9% | |||
| Chernett Jorey 13D/A | 0.6% |
10/2/2026
Event 9/30/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 916 | $1.60 k |
| 2026 Q2 | 92 | 15.3 M | $78.9 M |
| 2026 Q1 | 102 | 14.7 M | $139 M |
| 2025 Q4 | 94 | 15.2 M | $108 M |
| 2025 Q3 | 97 | 14.0 M | $113 M |
| 2025 Q2 | 96 | 14.6 M | $85.8 M |
| 2025 Q1 | 103 | 16.1 M | $196 M |
| 2024 Q4 | 98 | 15.2 M | $192 M |
| 2024 Q3 | 90 | 14.3 M | $129 M |
| 2024 Q2 | 79 | 13.4 M | $161 M |
| 2024 Q1 | 97 | 14.5 M | $264 M |
| 2023 Q4 | 94 | 12.9 M | $406 M |
| 2023 Q3 | 70 | 12.4 M | $188 M |
| 2023 Q2 | 73 | 11.6 M | $179 M |
| 2023 Q1 | 70 | 10.4 M | $96.9 M |
| 2022 Q4 | 53 | 10.3 M | $190 M |
| 2022 Q3 | 40 | 10.5 M | $98.2 M |
| 2022 Q2 | 41 | 10.9 M | $65.5 M |
| 2022 Q1 | 56 | 12.1 M | $72.3 M |
| 2021 Q4 | 55 | 12.9 M | $158 M |
| 2021 Q3 | 51 | 14.1 M | $587 M |
| 2021 Q2 | 62 | 14.2 M | $399 M |